tiprankstipranks
Aadi Bioscience reports Q4 EPS (52c), consensus (71c)
The Fly

Aadi Bioscience reports Q4 EPS (52c), consensus (71c)

Reports Q4 revenue $5.2M, consensus $4.65M. Reports cash, cash equivalents and short-term investments as of December 31, 2022 were $172.6M as compared to $148.9M as of December 31, 2021, which is expected to fund operations into 2025 based on current plans. "2022 was a year marked by successive milestones with the launch of FYARRO, the start of the PRECISION 1 trial, strengthening our balance sheet with a $72.5M financing, taking our cash runway into 2025, and collaborating on a new combination of nab-sirolimus with Mirati’s adagrasib," said Scott Giacobello, CFO and interim President and CEO of Aadi Bioscience. "We look forward to another year of advancements as we enter 2023 including the progression in our first collaboration, which is expected to initiate in the second quarter. As planned, we will provide preliminary data on patients in the PRECISION 1 trial in the Q2 of 2023."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on AADI:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles